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Abstract
Purpose There is a lack of robust and clinically utilizable
markers for the diagnosis and prognostication of malignant
pleural mesothelioma (MPM). This research was aimed at
optimizing and exploring novel approaches to improve the
diagnosis and prognostication of MPM in pleural effusions
and peripheral blood samples.
Methods CellSearch-based and flow cytometry-based assays
using melanoma cell adhesion molecule (MCAM) to identify
circulating tumor cells (CTCs) in pleural effusions and periph-
eral blood samples of MPM patients were optimized, validat-
ed, explored clinically and, in case of pleural effusions, com-
pared with cytological analyses. Additionally, tumor-
associated circulating endothelial cells (CECs) were measured
in peripheral blood samples. The assays were performed on a
MPM cohort encompassing patients with histology-confirmed
MPM (n=27) and in a control cohort of patients with alterna-
tive diagnoses (n=22). Exploratory analyses on the prognostic
value of all assays were also performed.
Results The malignancy of MCAM-positive cells in pleural
effusions from MPM patients was confirmed. The detection of
MPM CTCs in pleural effusions by CellSearch showed a poor
specificity. The detection of MPMCTCs in pleural effusions by
flow cytometry showed a superior sensitivity (48%) to standard
cytological analysis (15%) (p = 0.03). In peripheral blood, CTCs
were detected in 26% of the MPN patients, whereas in 42% of
the MPM patients tumor-associated CECs were detected above
the upper limit of normal (ULN). In exploratory analyses the
absence of CTCs in pleural effusions, and tumor-associated
CECs in peripheral blood samples above the ULN, appeared
to be associated with a worse overall survival.
Conclusion MCAM-based flow cytometric analysis of pleu-
ral effusions is more sensitive than routine cytological analy-
sis. Flow cytometric analysis of pleural effusions and tumor-
associated CECs in peripheral blood may serve as a promising
approach for the prognostication of MPM patients and, there-
fore, warrants further study.
Keywords Malignant pleural mesothelioma . Pleural
effusion . Circulating tumor cells . Circulating endothelial
cells . Tumor endothelial marker
1 Introduction
Malignant pleural mesothelioma (MPM) is an aggressive
and treatment-resistant asbestosis-induced neoplasm, of
which the incidence is expected to increase in the next
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years [1]. Diagnosing MPM can be challenging.
Especially the distinction between benign and malignant
mesothelial proliferation can be extremely difficult [2].
While markers to improve diagnosis such as mesothelin,
hyaluronan and osteopontin in plasma and pleural effu-
sions have been described [3–6], they are currently not
widely used in the clinic. Furthermore, despite the initial-
ly encouraging reports on fibulin-3 [7], the use of this
diagnostic marker turned out to be disappointing in clin-
ical practice [8]. MPM patients often present with pleural
effusions, but the sensitivity to diagnose MPM using fluid
cytology alone varies widely and has been reported to be
as low as 26% and as high as 73% [9–11]. While fluid
cytology is sometimes used to establish the diagnosis of
MPM, performing a pleural biopsy with histological sam-
pling is still recommended by the ESMO Clinical Practice
Guidelines to definitively diagnose MPM [12]. A pleural
biopsy, either performed by video-assisted thoracic sur-
gery (VATS) or by an open procedure is, however, an
invasive procedure with an associated morbidity, and even
when adequate tissue is obtained it can be difficult to
conclusively diagnose MPM [13].
In addition to the abovementioned difficulties in diagnosing
MPM, another clinical challenge is the current lack of robust
prognostic or predictive biomarkers for MPM [14], which limits
the options to further personalize the treatment ofMPMpatients.
Putative interesting tools to improve the diagnosis and prognos-
tication of patients with MPM include the assessment of
(circulating) tumor cells (CTCs) or circulating endothelial cells
(CECs) in pleural effusions and/or in peripheral blood.
CTCs are tumor cells that can be detected in the peripheral
circulation of patients with solid malignancies, and a robust
prognostic value of CTCs has been demonstrated for various
tumor types [15–17]. Of the currently available assays for
CTC detection, the CellSearch CTC test is the only one that
has been approved by the US Food and Drug Administration
(FDA). Through this test, tumor cells are isolated by
immunomagnetic enrichment from body fluids using
ferrofluid nanoparticles coated with epithelial cell adhesion
molecule (EpCAM)-specific antibodies. We previously dem-
onstrated that in breast cancer, melanoma cell adhesion mole-
cule (MCAM or CD146) may serve as an alternative marker
that is expressed in EpCAM-negative cells [18], and that a
modification in the CellSearch CTC enumeration kit can be
used to detect MCAM-positive CTCs in breast cancer patients
[19]. Expression of MCAM in cytological smears of pleural
effusions of MPM patients has been suggested as a novel
marker to discriminate between malignant and reactive meso-
thelium [20]. So far, however, the malignant nature of
MCAM-positive cells has not been confirmed, and sensitivity
issues are likely to play a role in MPM patients with a low
occurrence of tumor cells in pleural effusions when preparing
cytological smears. Therefore, the use of a CellSearch
MCAM-based enrichment approach may be instrumental to
specifically detect MPM cells at low concentrations in pleural
effusions and peripheral blood samples of MPM patients.
CECs are endothelial cells that have been sloughed of ves-
sel walls, and have been found to be increased in circulating
blood samples of patients with solid malignancies [21, 22].
Recently, we introduced a novel marker, CD276, to distin-
guish CECs derived from normal endothelium from those that
are tumor-derived [23]. Especially since MPM is a well-
vascularized tumor and angiogenesis is thought to be impor-
tant in MPM [24], tumor-associated CECs may serve as a
prognostic marker in MPM [25].
This research aimed to optimize techniques to detect tumor
cells in pleural effusions and peripheral blood samples of
MPM patients, and to obtain more insight into the potential
use of CTCs and CECs detected by these techniques as bio-
markers in MPM. Data are presented on a cohort of patients
with pleural effusions due to MPM and a cohort of patients
with pleural effusions due to other causes. In all cases, the
pleural effusions were evaluated using MCAM-based
methods in conjunction with CellSearch and flow cytometry.
Additionally, MPM patient-derived peripheral blood samples
were evaluated for the presence ofMCAM-positive CTCs and
tumor-associated CECs.
2 Material and methods
2.1 MCAM expression and recovery of MPM tumor cells
Three primary MPM-derived cell lines (MESO-1, MESO-2,
MESO-4; MPM cells isolated from human pleural effusion
samples) were stained with MCAM-APC (clone 541–10B2;
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) after
which MCAM-positive cells were recovered using a FACS
Fortessa flow cytometer (BD Biosciences, San Jose, CA,
USA). Subsequently, MCAM expression was quantified rela-
tive to unstained cells (signal/noise) using the FCS Express
tool (De Novo Software, Los Angeles, CA, USA). To deter-
mine the recovery of mesothelioma cells by CellSearch tech-
nology (Janssen Diagnostics, Raritan, NJ, USA) using
MCAM-based enrichment, 100 cells of the MPM-derived cell
lines were spiked into 7.5 ml healthy donor blood in duplo.
Subsequently, MCAM-based CTC enumeration was per-
formed as described before [18, 19]. Briefly, to enumerate
MCAM-CTCs the anti-EpCAM ferrofluids from the
Circulating Epithelial Cell Kit (Janssen Diagnostics) were
substituted with anti-MCAM ferrofluids from the Circulating
Endothelial Cell Kit (Janssen Diagnostics). Other components
of the Circulating Epithelial Cell Kit were left untouched,
meaning that cells were stained according to the standard
Circulating Epithelial Cell protocol with cytokeratin (CK)
8/18/19, DAPI (for nuclear staining) and CD45 (for exclusion
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of leukocytes). As an extra marker we used FITC-conjugated
CD34 (BD Biosciences, San Jose, CA, USA) to exclude
CK18-expressing CECs. MCAM-positive tumor cells were
thus defined as CK8/18/19+, DAPI+, CD45- and CD34- after
enrichment for MCAM.
2.2 SNP array analysis
Pleural effusions were flow cytometrically sorted using a
FACS Aria sorter (BD Biosciences). The following popula-
tions were sorted: 1) MCAM+, DRAQ5+ and CD45- cells; 2)
MCAM-, DRAQ5+ and CD45- cells and 3) CD45+ cells
(leukocyte control; see Supplementary Fig. 1). DNAwas iso-
lated from these populations using a Nucleospin DNA kit
(Macherey-Nagel, Düren, Germany) and DNA concentrations
were quantified using a Qubit dsDNA HS Assay kit (Thermo
Fisher, Waltham, MA, USA). Next, DNA from these popula-
tions was subjected to SNP array analysis using a CytoScan
HD Array Kit (Affymetrix, Santa Clara, CA, USA). The SNP
array data were subsequently analyzed for the presence of
copy number variations (CNVs) using the Chromosome
Analysis Suite (ChAS) software (Affymetrix).
2.3 Patients and inclusion criteria
Two cohorts of patients were included in this prospective
study. The first cohort (MPM cohort) consisted of patients
with pathology-confirmed MPM or a high suspicion of
MPM, presenting with pleural effusions who needed to
undergo a pleural drainage or video-assisted thoracoscopy
as part of standard care. The second cohort (control co-
hort) consisted of patients who presented with pleural ef-
fusions with a need to drain as part of standard care and in
whom an established diagnosis other than MPM was
made. In all cases the pleural effusions were sent to a
pathological laboratory and processed as a part of stan-
dard care. Additionally, in all cases 20 ml of pleural effu-
sion residual material was sent for MCAM-based CTC
enumeration and FC. In the MPM cohort also 2 × 10 ml
peripheral blood was drawn for MCAM-based CTC enu-
meration and CEC enumeration. This study ran from
March 2014 to January 2016 in two centers in
The Netherlands (Erasmus MC Cancer Insti tute,
Rotterdam, The Netherlands and Amphia Hospital,
Breda, The Netherlands). All patients provided written
informed consent, and the institutional boards of both
participating centers approved the protocols (Erasmus
MC ID MEC-2014-116; Netherlands Trial Register
NTR4575). All procedures involving human participants
were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or
comparable ethical standards.
2.4 Processing of pleural effusion and peripheral blood
samples
Pleural effusions were processed for standard cytology analy-
sis as part of standard care. All pleural effusion cytology slides
were revised by one pathologist (MdB), who is a member of
the Dutch national mesothelioma expert pathology panel.
Pleural effusions for research purposes were first filtered on
a Falcon Cell Strainer (70 uM; Corning Incorporated,
Corning, NY, USA) to remove cell clumps and debris and
processed within 24 h after the pleural drainage. Peripheral
blood was drawn in CellSave tubes, and processed within
96 h for MCAM-CTC enumeration and CEC enumeration.
The MCAM-based CTC enumeration in pleural effusions
(3 ml) and peripheral blood samples (7.5 ml) was performed
as described above and before [18, 19]. As the CellSearch
system requires an area in which red blood cells are present
to start processing the sample, a ‘dummy’ tube with the bot-
tom of the tube marked black (marking the area in which
packed red blood cells are expected) was used to process the
erythrocyte-poor pleural effusions samples on the CellSearch
system after centrifugation. CK+, DAPI+, CD45- and CD34-
were considered positive events as described before [19]. In
case 5 or more cells were closely connected to each other, the
event was counted as a cluster.
For flow cytometry of the pleural effusion samples, 10 ml
filtered pleural effusion waswashed twice in phosphate buffered
saline (PBS) and resuspended in 1 ml PBS supplemented with
1% bovine serum albumin. Subsequently, 100 ul of the suspen-
sion was stained using our pleural effusion antibody panel
encompassing MCAM, pan-cytokeratin (pan-CK), CD45,
CD34, two MPM-specific markers thrombomodulin (CD141)
and podoplanin (D2–40) and two carcinoma-specific markers
CEA (CD66e) and Claudin-4, and DAPI (Supplementary
Tables 1 and 2). All antibodies were carefully titrated using
positive and negative controls. As DAPI and pan-CK stain in-
tracellular, they were employed after fixation and perme-
abilization of the cells using a FIX&PERM Cell fixation and
permeabilization kit (Nordic-MUbio, Susteren, the Netherlands)
according to the manufacturer’s instructions. The samples were
loaded on an FACS Fortessa flow cytometer (BD Biosciences)
and analyzed in FCS Express (De Novo Software). Cells that
were MCAM+, DAPI+, pan-CK+, CD45- and CD34- were
considered as putative MPM tumor cells (see gating strategy
in Supplementary Fig. 2). When these cells were also negative
for the carcinoma-specific markers used, they were considered
to be true MPM tumor cells. Positivity was evaluated against
unstained controls for each fluorochrome, and positivity for the
MPM and carcinoma-specific markers was defined as ≥ 20% of
the putative MPM tumor cells being positive for that marker.
The enumeration of CECs was performed in 4 ml periph-
eral blood as described before [22, 23]. Cells that were CD34+
, DRAQ5+, MCAM+ and CD45- were defined as CECs, and
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CECs also expressing CD276 were defined as tumor-
associated CECs.
2.5 Statistical considerations and analyses
Our primary objective was to increase the sensitivity of pleural
effusion evaluation in MPM using MCAM-based CellSearch
CTC enrichment compared tomanual fluid cytology evaluation.
Based on reports on the expression of MCAM in both tissue
[26] and pleural effusion specimens [20] of MPM patients,
which has been reported to be > 80%, we assumed that a sen-
sitivity of at least 80% could be reached using the CellSearch
enrichment technology. According to literature data, fluid cytol-
ogy by a pathologist has a sensitivity of approximately 30%.We
powered the study according to a statistical worst-case scenario
of discordant proportions of 0.2 and 0.7 using the McNemar
test, and 34 patients with a confirmed diagnosis of MPMwould
be needed to reach significance at a level of α = 0.05 and
β = 0.10. Twenty patients with pleural effusion due to another
cause than MPM were included to explore the specificity of the
test. Secondary objectives of the study were to confirm the
malignant nature of MCAM-positive tumor cells in pleural ef-
fusions, to develop a flow cytometric strategy on pleural effu-
sions to diagnose MPM, to investigate the presence of CTCs
and tumor-associated CECs in peripheral blood samples, and to
perform exploratory analyses on the prognostic value of all
measured biomarkers in the context on this study. The numbers
of cells between the two cohorts were compared using the
Mann-Whitney U test, and the presence or absence of a bio-
marker between the two groups was compared using a χ2 test.
All reported p-values are two-sided, and a significance level
α = 0.05 was used. All constructed Kaplan-Meier curves are
exploratory as the number of patients and events was low and no
formal statistics could be performed on the curves. All data
analyses were done using Stata/SE version 12 (StataCorp LP,
College Station, TX, USA).
3 Results and discussion
MCAM expression was evaluated in three primary MPM-
derived cell lines. Two cell lines (MESO-2 and MESO-4)
were found to show a high MCAM expression, while one cell
line (MESO-3) showed a moderate to low expression. The
recovery of mesothelioma cells spiked into peripheral blood
samples using the MCAM-based CellSearch technology (per-
formed in duplicate for each cell line) was 48–63% for the two
MPM cell lines with a highMCAM expression (MESO-2 and
MESO-4) and 4–8% for the MPM cell line with low MCAM
expression (MESO-3).
To confirm the malignant nature of MCAM positive cells in
pleural effusions, pleural effusions from six patients with a
pathology-confirmed diagnosis of MPM were flow
cytometrically sorted for subsequent SNP array analysis. In
two flow cytometrically sorted MCAM-positive fractions from
two separate patients a sufficient amount of DNA was present
for reliable SNP array analysis. We found that the MCAM-
positive populations (MCAM+, DRAQ5+, CD45-) of both
these patients exhibited a number of CNVs, while the leukocyte
populations from the same patients did not exhibit these CNVs,
as expected (Supplementary Fig. 3). These results demonstrated
the putative malignant nature of the MCAM-positive tumor
cells in the pleural effusions of the MPM patients and led to
the initiation of the clinical study described below.
A total of 49 patients was included. The MPM cohort
consisted of 27 patients, and the control cohort of 22 patients
(Table 1). The patients in the control cohort represented a
mixed population with regard to malignant pleural effusions
(52%) and benign pleural effusions (48%). In the MPM co-
hort, the majority of the patients had an epithelial type MPM
(81%). The MPM patients were evenly distributed between
stage I-II (52%) and stage III-IV (48%) and most of them
(70%) did not receive any prior MPM treatment.
Pleural effusions of 41 patients could be evaluated using
CellSearch MCAM-based enrichment. Cells meeting our
criteria for being tumor cells were detected in 21 of 23 patients
Table 1 Baseline characteristics
MPM cohort
(n = 27)
Control cohort
(n = 22)
Diagnosis
Malignant pleural mesothelioma 27
Epithelial malignancy 9
Non-epithelial malignancy other
than mesothelioma
3
Benign 10
Gender
Female (%) 1 (4%) 8 (36%)
Age
Years (range) 70 (27–90) 67 (30–91)
WHO stage
WHO 0–1 14 11
WHO 2 11 8
WHO 3 2 3
Smoking
Never 9 6
Past 10 11
Current 8 5
Asbestosis exposure
No 7 3
Yes 20 6
Unknown 0 13
Pathology
Epithelial MPM 22
Biphasic MPM 5
Stage
MPM stage I-II 14
MPM stage III-IV 13
Prior treatments for MPM
No 19
Yes 8
Currently on treatment for MPM
No 23
Yes 4
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(91%) from the MPM cohort and in 17 of 18 patients (94%)
from the control cohort. The median number of cells was 416/
3 ml in the MPM cohort and 440/3 ml in the control cohort
(p = 0.86). Cell clusters were present in 15 patients (65%) from
the MPM cohort and in 11 patients (61%) from the control
cohort (p = 0.79).
Using flow cytometry, tumor cells meeting our criteria for
being MPM tumor cells (i.e., MCAM+, CK+, DAPI+, CD45-,
CD34-, CEA-, Claudin-4-) were detected in the pleural effu-
sions from 12 of 25 patients in the MPM cohort (48%). Also
in one patient (6%) from the control cohort these cells were
detected, leading to a specificity of 94%. The median number
of MPM tumor cells in the MPM patients was 337 (range 23–
10,017). NoMPM tumor cells were detected in 4 patients with a
biphasic MPM histology. In the majority of MPM patients the
tumor cells expressed thrombomodulin (92%), whereas
podoplanin expression on these cells was observed in the pleural
effusion of only one patient (8%). We found that the MPM
tumor cells expressed EpCAM in 33% of the cases and
GLUT1 in 58% of the cases. Of note, we found that in the
control cohort two patients hadMCAM-positive cells, not meet-
ing the criteria for MPM tumor cells given a strong expression
of the epithelial markers CEA and Claudin-4, suggesting that
these might be carcinoma cells. As it turned out, these patients
indeed had metastatic epithelial cancers (breast cancer and thy-
roid cancer, respectively).
The above flow cytometric observations were compared to
those of the pathologist, which is the current clinical standard.
Paired observation data were present from 20 patients in the
MPM cohort and 18 patients in the control cohort. The pathol-
ogy review correctly identified 3 MPM patients as having
MPM, whereas none of the patients in the control cohort were
scored as having MPM, yielding a sensitivity of 15% and a
specificity of 100%. The flow cytometric assay identified 6
additional MPM patients compared to those identified by the
pathology reviews of the pleural effusions (Table 2, McNemar
p = 0.03). An exploratory survival analysis revealed that the
MPM patients in whomMPM tumor cells were detected using
flow cytometry may have a better overall survival (OS) than
patients in whom these cells were not detected (Fig. 1).
Circulating tumor cells (CTCs) were detected in 6 of 23
MPMpatients (26%). In five patients one CTC per 7.5 ml blood
was detected, while in one patient 3 CTCs/7.5 ml were detected.
Two patients with CTCs had stage I-II disease, whereas the
other 4 patients with CTCs had stage III-IV disease. Four of
the patients with CTCs had received prior chemotherapy.
Circulating endothelial cell (CEC) enumeration results were
available for 24 MPM patients. The median number of CECs
was found to be 37/4 ml (range 3–179). The tumor-associated
marker CD276 was expressed in a median of 24% (range 7–
78%) of the CECs, resulting in 10 patients (42%) having tumor-
associated CECs higher than the upper limit of normal (ULN; ≥
8 tumor-associated CECs/4 ml [23]). Four of these patients had
stage I-II disease, and 6 patients had stage III-IV disease.
Through exploratory survival analyses, we found that the
presence of CTCs or a CEC number above the median did not
appear to be associated with overall survival (OS). The pres-
ence of tumor-associated CECs higher than the ULN may,
however, be associated with OS (Fig. 2).
Table 2 Pathology review versus FC assay for patients with MPM in
whom matched cytology and FC results from PE obtained on the same
day were available
FC positive
for MPM
FC negative
for MPM
Total
PA positive for MPM 3 0 3
PA negative for MPM 6 11 17
Total 9 11 20
Fig. 1 Overall survival according
to the detection of tumor cells in
pleural effusions using flow
cytometry in the MPM cohort
Biomarkers in MPM
Both the diagnosis and the treatment of MPM patients are
hampered by the limited availability of biomarkers that are clin-
ically useful. Here, we presented and validated techniques to
identify tumor cells in pleural effusions and peripheral blood
samples of MPM patients and, subsequently, explored whether
detecting these tumor cells in pleural effusions might improve
the diagnosis of MPM, and whether enumerating CTCs and
CECs improves the prognostication ofMPMpatients.We found
that enumeration of tumor cells in pleural effusions using the
FDA-cleared CellSearch machine provided a limited specificity.
Using flow cytometry, a higher sensitivity than with standard
pathological assessment was observed, and this sensitivity was
accompanied by an acceptable specificity. Additionally, we
found through exploratory analyses that flow cytometry-based
enumeration of tumor cells in pleural effusions and a similar
enumeration of tumor-associatedCECs in peripheral blood sam-
ples may have prognostic value.
It was hypothesized that the sensitivity and specificity for
diagnosing MPM could be improved by enriching for the pre-
sumed MPM-specific marker MCAM. The malignant nature of
MCAM-positive cells was confirmed using flow cytometric
sorting in conjunction with genomic analyses (i.e., SNP-based
DNA copy number profiling). The CellSearch system was cho-
sen to enrich and enumerate these cells since MCAM-specific
enrichment was already up-and-running on this machine [18,
19]. Using this latter technique, however, we noted that a vast
number of non-mesothelioma pleural effusions contained rela-
tively high numbers of cells meeting the criteria for tumor cells.
This limited specificity of the CellSearch system is in accordance
with observations reported by Lustgarten and colleagues [27].
This group attempted to improve the diagnosis of malignant
pleural effusions by the CellSearch system using EpCAM to
enrich for CTCs. By doing so, they detected up to 2556
EpCAM-positive cells/3 ml in patients with benign effusions
and non-epithelial effusions. Since in the present study high
numbers of cells were scored with the CellSearch system in
patients who had no detectableMCAM-positive cells using flow
cytometry, we hypothesize that the reactive mesotheliummay be
a-specifically enriched when it is excessively present in the pleu-
ral effusions. When one of the pleural effusion samples was
treated with immunoglobulins prior to CellSearch enrichment
to block a-specific binding ofMCAMantibodies to Fc receptors,
Fig. 2 Overall survival in the MPM cohort according to biomarkers in peripheral blood. a patients separated by the median number of CECs. b patients
above and below the upper limit of normal for tumor-associated CECs. c overall survival according to the presence of CTCs
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60% less cells were observed than in samples not treated with
immunoglobulins. These findings suggest that a-specific binding
of reactive mesothelium through Fc receptor binding may, at
least partly, explain the limited specificity of the CellSearch sys-
tem. This limited specificity led to an early discontinuation of
this part of the study, since obviously the primary study endpoint
could not be reached. Using flow cytometry, however, a better
specificity than with the CellSearch system was obtained. In
addition, we found that the flow cytometry assay exhibited an
improved sensitivity over standard cytological analyses.
However, where the cytological analyses yielded a 100% spec-
ificity, the flow cytometry assay yielded one false-positive find-
ing, leading to a 94% specificity. This latter finding should,
however, be interpreted with caution since next to the presence
of a benign mesothelial proliferation, this patient was clinically
suspect for MPM. During a follow-up period of 1.5 years, how-
ever, MPM did not become manifest c.q. was not pathologically
confirmed.
In the past years ample research has been devoted to the
identification of novel markers to diagnose MPM in pleural
effusions, but so far none of the identified markers has been
widely incorporated in clinical practice. Recently, others have
reported that p16 FISH and BRCA1-associated protein 1
(BAP1) immunohistochemistry-based assays may improve
the sensitivity of pleural effusion cytology, with a sensitivity
of 45% to 84% for p16 and of 33% to 74% for BAP1 [28]. The
sensitivity of the flow cytometric assay used in the current
study falls within the range of these assays. In addition, we
found that the sensitivity of the flow cytometric assay used is
comparable with that of the detection of tumor antigens in
pleural effusions as recently evaluated in a meta-analysis
[29]. Unfortunately, no cytological slides were available to
compare the flow cytometry assay with MCAM (or other
marker) staining results. Of note, we found that the numbers
of MPM tumor cells in the pleural effusions detected by flow
cytometry were often low, indicating that there may be a small
chance to detect them through standard cytological analyses.
Surprisingly, we found that patients with MPM tumor cells
in their pleural effusions as detected by flow cytometry exhib-
ited an improved OS compared those in which these tumor
cells were not detected. There are two possible explanations
for this observation: 1) MCAM is a marker for a good prog-
nosis; 2) the presence of MPM tumor cells in pleural effusions
is related to an increased chance of response to therapy.
Obviously, validation of this preliminary finding and, when
confirmed, exploration of the underlying reason in a larger
cohort will be necessary.
In a quarter of the patients CTCs were detected in periph-
eral blood samples using our MCAM-based enrichment
method. This CTC-positivity rate was lower than that previ-
ously reported by others using standard EpCAM-based CTC
enrichment. Yoneda et al. [30] reported that 33% of their
MPM patients had EpCAM-positive CTCs, while Raphael
et al. [31] detected EpCAM-positive CTCs in 44% of their
MPM patients. Since MCAM is more widely expressed than
EpCAM in MPM tissues, the lower CTC-positivity rate as
observed here is surprising. This discrepancy may be ex-
plained by the inclusion of more patients with stage IV
disease in both studies evaluating EpCAM-positive CTCs
than in the current study. Our observations, along with the
observations regarding EpCAM-positive CTCs, suggest that
the presence of CTCs is limited in patients with MPM,
which is also reflected by the fact that clinically detectable
metastasis outside the thorax is a relatively rare and late
event in MPM [32]. The presence of MCAM-positive
CTCs did not appear to be associated with OS in an explor-
atory cohort analysis. Also, the presence of CECs above the
median did not appear to be related to OS. Only when
tumor-associated CECs were analyzed they seemed to be
of prognostic value for OS. Yoneda et al. [25] previously
reported a modest relation between poor OS and high CEC
numbers in a cohort of 79 MPM patients. Our findings on a
much smaller cohort of patients suggest that when a marker
specific for tumor-associated CECs is added, i.e., excluding
CECs derived from the normal vasculature [33], the prog-
nostic power of CECs may improve.
In conclusion, we show in this exploratory study that
MCAM-positive cells in pleural effusions of patients with
MPM are malignant in nature, and that several biomarkers
may be used to improve the diagnosis and prognostication
of patients with MPM. The enumeration of tumor cells and
tumor-associated CECs may lead to an improvement of both.
Our results warrant a further investigation of larger MPM
cohorts.
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